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Although Crohn’s disease (CD) etiology remains unclear, a growing body of evidence suggests that CD may include
an infectious component, with Mycobacterium avium subsp. paratuberculosis (MAP) being the most likely candidate
for this role. However, the molecular mechanism of the MAP involvement in CD pathogenesis remains unclear.
The polymorphism of the NOD2 gene, coding for an intracellular pattern recognition receptor, is a factor of
predisposition to mycobacterial infections and CD. Recent findings on NOD2 interactions and functions provide
the missing pieces in the puzzle of a NOD2-mediated mechanism common for mycobacterial infections and CD.
Implications of these new findings for the development of a better understanding and treatments of CD and
mycobacterial infections are discussed.
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Crohn’s disease (CD) is a systemic inflammatory disease
involving primarily the intestinal tract and associated
with the variety of extraintestinal manifestations. Al-
though it may affect any part of the digestive tract from
the mouth to the anus, it most commonly affects the last
part of the small intestine (ileum) and/or the large in-
testine (colon and rectum). The etiology of CD remains
unclear. However, there is phenotypical, epidemiological
and clinical evidence of Mycobacterium avium subsp.
paratuberculosis (MAP) involvement in CD development
[1-3]. This enteric pathogen is significantly associated with
CD [4-7]. MAP causes paratuberculosis (Johne’s disease),
a chronic, contagious bacterial disease that primarily af-
fects the small intestines of ruminants. Johne’s disease af-
fects approximately 68% and 32% of cows in the USA and
the UK, respectively [7,8]. Live MAP is found even in pas-
teurized cow’s milk, suggesting that dairy products and
beef, widely present in the “western” diet, can play a roleCorrespondence: alexey.nabatov@maastrichtuniversity.nl
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unless otherwise stated.in MAP transmission to human population [1]. The lack
of evidence for horizontal or vertical transmission of CD
suggests that MAP is a zoonotic agent or an opportun-
istic pathogen in humans [9]. The signs of Johne’s dis-
ease in ruminants are similar to the symptoms of CD.
Moreover, CD demonstrates a striking similarity of symp-
toms to intestinal tuberculosis caused by M. tuberculosis,
Mtb [10-12].
The systemic characters of CD and mycobacterial in-
fections suggest that the underlying pathological pro-
cesses are defects in basic cellular signaling mechanisms
common to different cell types. However, these molecu-
lar mechanisms remain unclear. As a result, CD remains
incurable and its incidence increases around the globe,
which makes CD a global health problem with high soci-
etal costs and a substantial health-related quality-of-life
burden [13,14]. The recent rapid growth of CD inci-
dence in Asia may be related to the westernization of
the diet and an improved hygiene [15].
The polymorphism of Nucleotide binding and Oligo-
merization Domain 2 (NOD2) is a genetic predisposition
factor for both CD and mycobacterial infections [16-20].
However, it does not seem to contribute significantly to
the CD incidence in Eastern Asians, probably due to thes is an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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polymorphisms in this part of the world (Rs2066844;
Rs2066845; Rs2066847 (Rs5743293)) [15,21,22]. These
facts suggest that NOD2 polymorphism is rather sec-
ondary for disease development, which, however, does
not exclude a NOD2 role in CD etiology.
It is prompting to speculate that NOD2 mediates a
mechanism important for both mycobacterial infection
and CD. However, until recently, little was known about
what basic NOD2-dependent mechanism could link CD
and mycobacterial infection and at the same time ex-
plain the characteristic features of these diseases. Several
years ago it became clear that, to prove the mycobacter-
ial hypothesis of CD, immunologists should identify the
microbe-associated ligands mediating CD immune de-
fects [23]. In the last two years, this gap in understand-
ing of CD etiology has been filled for NOD2. This
review for the first time summarizes the new findings
linking NOD2, mycobacterial infection and CD develop-
ment, and explains some characteristic molecular features
of these diseases.
NOD2 and its ligands
The NOD2 (Blau, CARD15) gene encodes a 115-kDa
cytosolic protein with multiple C-terminal leucine-rich
repeats (LRR), a central NACHT (NAIP, CIITA, HET-E,
TP-1) domain, and two N-terminal caspase recruitment
domains (CARDs). The NACHT domain bears high hom-
ology to NTPase domains; however, the intrinsic NTPase
activity of the NACHT domain is not well established.
The NOD2 NACHT domain resembles the ATPase do-
main of the proton-pumping F1-ATPase, which in turn
is highly similar to that of Vacuolar-type H+-ATPase
(V-ATPase) [24,25]. The NACHT domain mediates
homo- and heterotypic oligomerization, which triggers
recruitment of pro-inflammatory factors (caspase-1 and
RIP2) to CARDs and enhances pro-inflammatory activity
at both the transcriptional and the post-transcriptional
levels [26-30]. Unbound to a ligand, the LRR domain
covers the NACHT domain and prevents the NACHT-
mediated oligomerization [29]. The genetic polymorph-
ism of the NOD2 LRR predisposes to CD whereas the
NACHT polymorphism is associated with deregulation
of NF-kB activity and development of Blau syndrome,
an inflammatory disorder that primarily affects the skin,
joints, and eyes [16,17,31].
Increased NOD2 expression alone can activate pro-
inflammatory NF-kB activity, suggesting a default char-
acter of this NOD2 activity [28,32]. The baseline gene
expression of NOD2 is very low in different cell types,
reflecting the specific and powerful characters of the
NOD2 regulated processes [33]. Indeed, NOD2 gene ex-
pression is up-regulated under stress conditions such as
hypoxia or the presence of bacterial lipopolysaccharides,both known to regulate the transcriptional activity of
hypoxia-inducible factor type 1 (HIF-1) [32,34-36].
NOD2 also mediates autophagy, a catabolic intracellular
process of partial cytoplasm sequestration into double-
membrane autophagosomes that fuse with lysosomes to
digest the sequestered material [37,38]. Muramyl dipep-
tide (N-acetylmuramyl-L-alanyl-D-isoglutamine), a frag-
ment of the bacterial cell wall, seems to be an unspecific
NOD2 activator inducing both pro-inflammatory and
autophagy activities [26-29,37,38]. The processes of in-
flammation and autophagy are antagonistic to each other
[39]. For NOD2, it may mean that NOD2 mediates in-
flammation by default if it is not involved in autophagy.
NOD2 belongs to the family of pattern recognition
receptors (PRRs) serving as innate immunity sensors.
PRRs recognize a limited number of conservative im-
munogenic epitopes (patterns) including endogenous
damage-associated molecular patterns, DAMPs [40-42].
Autophagy-inducing cytoplasmic PRRs can specifically
recognize host glycans from the outer leaflets of mem-
branes when membrane damage (i.e. caused by patho-
gens) exposes the outer glycans to the cytoplasm [43].
These findings may shed additional light on the sentinel
role of NOD2 at the host membranes [44].
3-O-sulfogalactocerebroside (sulfatide), a sphingolipid
normally present on the outer membrane leaflet, has re-
cently been identified as the first NOD2 DAMP mediat-
ing NOD2 involvement in autophagy [32]. Of interest,
hypoxia also stimulates the gene expression of GAL3ST1
(Galactose-3-O-sulfotransferase 1), whose protein prod-
uct catalyzes the conversion of 3’-phosphoadenosine-5’-
phosphosulfate (PAPS) + galactosylceramide to adeno-
sine 3’,5’-bisphosphate + sulfatide [32]. These findings are
in line with others showing that renal carcinoma cells,
known for their deregulated activity of HIF-1, have ele-
vated sulfatide and sulfotransferase activities [45,46].
Thus, the co-expression of NOD2 and GAL3ST1 pre-
pares vulnerable membranes to effective recognition by
NOD2 and subsequent autophagy if the membranes be-
come damaged.
NOD2 vesicle-associated function
Intracellular vesicle-associated acidity grows under hyp-
oxia [47]. This vesicle acidity is mediated by the V-ATPase
proton-pumping catalytic activity. These newly formed
vesicles need to protect their acidity because the hypoxia-
associated ATP deficiency can induce vesicle leakage [48].
However, the V-ATPase function is not limited to pro-
ton pumping. Assembled but inactive V-ATPase mediates
vesicle content storage, whereas its disassembly mediates
vesicle fusion and content release (including leakage)
[49-52]. NOD2 deficit decreases the intracellular vesicle
acidity but not vesicle acidification, suggesting a NOD2
role in vesicle content storage. NOD2 interacts with
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NOD2 – V-ATPase complex reaches sulfatide-rich mem-
branes, where the V-ATPase disassembles (Figure 1) [32].
These and more recent findings directly link NOD2 func-
tion to intracellular vesicles [53].
At high ATP concentrations, the catalytic activity of
V-ATPase may compensate for the lack of NOD2 func-
tionality by pumping the leaked protons back into the
vesicles. This makes NOD2 protein dispensable for nor-
mal conditions, which is supported by the very low NOD2
gene expression in normal conditions. However, stress
conditions associated with a deficit of ATP production
(e.g. hypoxia) will increase the need for the NOD2-
mediated energy-saving mechanism of proton storage
in vesicles.
The induction of “fusion-competent” vesicles after
NOD2-sulfatide interaction suggests their accumulation
in close proximity to damaged membranes. These vesiclesFigure 1 The model of NOD2 vesicle-associated function. 1) Catalytical
(big circle) sectors pumps (big dotted arrow) protons from the cytoplasm i
state; 2) NOD2 may substitute for the catalytic V1A subunit (stripped oval)
V-ATPase complex remains assembled. 3) A normal membrane keeps sulfat
4) When the membrane is damaged, it exposes sulfatide to the cytoplasm.
which induces V-ATPase complex disassembly and opens the fusion-mediamay provide membrane material and eventually direct
autophagosome growth specifically around the dam-
aged membranes, without sequestration of undamaged
areas (Figure 2). On the other hand, the presence of
sulfatide-mimicking agents at a distance from the sulfatide-
exposing membranes will inhibit the specificity of NOD2
function and induce unspecific fusion and vesicle content
release (leakage).
NOD2 and mycobacterial immune escape
Macrophages, professional antigen-presenting immune
cells expressing one of the highest amounts of NOD2 in
the body, are the preferred hosts for MAP and Mtb.
Whether active mycobacteria remain inside phagosomes
or translocate from phagosomes into the cytosole has
been a matter of debate in recent years [54]. In both
cases, mycobacteria should perforate the phagosomal
membrane to egress into the cytoplasm or to get accessly active V-ATPase consisting of transmembrane V0 and cytoplasmic V1
nto the vesicle. Cytoplasmic NOD2 (grey figure) is in the self-inhibiting
in the V-ATPase complex, when pumping is stopped and the rest of
ide (black-head “lipid”) on the outer (opposite to the cytoplasm) leaflet.
5) The sulfatide exposure to the cytoplasm is recognized by NOD2,
ting V0 sector, making the vesicle fusion-competent.
Figure 2 The activated by NOD2 vesicles in autophagy. 1) A phagosome containing a microbe (checkered figure) becomes damaged and 2)
exposes sulfatide to the cytoplasm. 3) Autophagy is initiated and fusion-competent vesicles are accumulated around the damaged phagosome
due to V-ATPase disassembly triggered by sulfatide-NOD2 interaction. 4) The fusion competent vesicles fuse with the autophagosome providing
material and directing autophagosome growth specifically around the damaged phagosome. The outer (sulfatide-containing) membrane leaflet is
grey; the inner membrane leaflet is black.
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vive, mycobacteria induce mechanisms that prevent or
subvert the membrane-damage-associated activation of
NOD2.
Mtb lipid virulence factors may have evolved to mimic
host lipids and thereby directly influence innate immune
responses of macrophages via interactions with specific
signaling pathways [56]. Mycobacteria synthesize a spe-
cific sulfolipid (SL-1) that mimics sulfatide in binding to
NOD2 [32]. This suggests that SL-1 interaction with
NOD2 can activate unspecific NOD2-mediated pro-
cesses of V-ATPse disassembly, making intracellular ves-
icles leaky and/or activating unspecific fusion of these
vesicles. This clarifies the SL-1-mediated inhibition of: 1)
lysosome fusion with Mtb-containing phagosomes and
2) lysosome maturation [57-59]. Subverting NOD2 ac-
tivity in the vesicle–associated function of NOD2 (i.e.
autophagy), SL-1 inevitably activates NOD2-mediated
inflammation, which can explain (at least partly) the
characteristic inflammation present in mycobacterial
infection [60,61].
Mtb lipids are abundantly produced during macro-
phage infection and are actively trafficked out of my-
cobacterial phagosomes [62]. Moreover, mycobacterial
lipids can be found in extracellular vesicles and could be
observed in uninfected ‘bystander’ cells, which expand
the bacteria’s sphere of influence beyond the membranes
of the infected host cell [62]. For CD pathogenesis, it
means that MAP-infected intestinal cells may conta-
minate with SL-1 surrounding intestinal cells, such as
enterochromaffin (EC) cells, Paneth cells, and their pro-
genitor stem cells, all of which are known to be affected
in CD [63,64].
In these circumstances, the NOD2 polymorphism
associated with decreased sulfatide recognition makes
the host predisposed to mycobacterial infections. Whenmycobacterial infection is established, the double pres-
sure on the NOD2 vesicle function from the polymorph-
ism and SL-1 substantially increases the chance of defects
in acidic vesicle homeostasis. Notably, the 1007 fs NOD2
polymorphism most commonly associated with predis-
position to CD, only slightly decreases the NOD2 bin-
ding to sulfatide, suggesting that SL-1 presence plays a
more important role in CD development than does
genetic predisposition [32]. Indeed, only about 5% of
NOD2 mutation homozygotes develop CD, suggesting
crucial roles for additional factors (like mycobacterial
infection) in CD development. Of interest, sulfonated
compounds like dextan sulfate and 2,4,6-trinitrobenze-
nesulfonic acid are used the most frequently for experi-
mental colitis induction.
Vesicle-associated abnormalities and CD specific features
We found NOD2 in cell-division-specific structures as-
sociated with the massive fusion of intracellular vesicles
providing the membrane material for cell division [32],
[65]. Cell division and a high level of autophagy, where
the latter maintains the stemness, are typical stem cell
features supported by the expression and functional ac-
tivities of proteins mediating these processes [66]. NOD2
has an important biological role in bone marrow CD34+
hematopoietic cells [67]. Intestinal crypt Lgr5+ stem cells
also express Nod2 mediating gut epithelial regeneration
[68]. The latter suggests that NOD2 regulates the Notch
signaling pathway, a key cell communication pathway that
suppresses production of secretory intestinal cells (i.e.
EC cells) in favor of higher gut epithelial cell produc-
tion [69]. Notch activity is promoted by the fusion of
Notch receptor-containing endosomes with V-ATPase-
containing lysosomes [70-72]. All this suggests that the
SL-1-associated unspecific activation of NOD2 in intes-
tinal stem cells may increase production of EC cells,
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(5-hydroxytryptamine).
CD-affected intestines have higher numbers of EC
cells and levels of serotonin [63,73]. Enteric serotonin is
a major gastrointestinal paracrine hormone and neuro-
transmitter mediating the peristaltic activity, blood clot-
ting and bone metabolism, all impaired in CD [74-78].
The systemic character of serotonin action in the body
suggests that imbalances of serotonin in CD can be
among the factors mediating the systemic character of
the disease. Serotonin imbalances are also found in lep-
rosy and tuberculosis [79,80].
V-ATPase generates the proton membrane potential
that is used by vesicular monoamine transporters to se-
quester newly synthesized or externally up-taken sero-
tonin into intracellular vesicles [81]. SL-1-induced vesicle
content leakage will lead to a prolonged exposure of non-
sequestered monoamines to cytoplasmic (mitochondrial)
monoamine oxidases. This results in an increased conver-
sion of monoamines into toxic aldehydes, causing cell
damage and inflammation. These effects in turn enhance
EC cell production from intestinal stem cells, making the
pathological process self-sustaining [82-84].
NOD2 and other genetic and non-genetic factors of
predisposition to CD
Mechanisms mediating serotonin release from cells be-
come very important when serotonin sequestration is
defective. Indeed, genetic polymorphisms of polyspecific
organic cation transporters OCTN1/2, translocating cyto-
plasmic serotonin through the cytoplasmic membrane, are
among the CD predisposition factors [85,86]. Moreover,
the CD-associated OCTN1 and NOD2 gene polymor-
phisms are additive for CD development [87].
Only about 10 to 20 percent of patients have a family
history of CD, suggesting the main role of environmental
factors in CD development. Similar to SL-1 competing
with sulfatide for NOD2 binding, other factors affecting
sulfatide synthesis or accessibility can trigger NOD2 func-
tional deficiency.
CD is more common in urban areas. In general, these
areas are better supplied with potable water, which, even
after chlorination, may serve as a transmission route of
MAP [88]. Chlorate ion (ClO3−), often used for or formed
as a byproduct in water chlorination, is a well-known in-
hibitor of PAPS synthesis and consequently sulfatide syn-
thesis. Exposure of cells to sodium chlorate has a similar
effect on autophagy as NOD2 deficiency [32]. Thus, the
hypothesis of MAP transmission via potable water should
include water chlorination as a risk factor.
Conclusion
The absence of a clear mechanistic explanation of the
role of MAP in CD has been one of the main obstaclesin transformation of their well-known association into
causation. NOD2, an intracellular pattern recognition re-
ceptor playing a role in mycobacterial infections and CD,
has been suspected as a possible link between them. This
review summarizes very recent findings on the NOD2 lig-
and and functional specificities that establish the causative
link between mycobacteria and CD via mycobacteria-
specific inhibition of NOD2 function. Moreover, these
findings clarify the role of other genetic and environ-
mental factors of predisposition to systemic CD. Further
development of these NOD2 findings may provide novel
therapeutic targets for CD and other mycobacteria-related
pathologies.
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